Page last updated: 2024-10-27

gabapentin and Alcoholism

gabapentin has been researched along with Alcoholism in 55 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)

Research Excerpts

ExcerptRelevanceReference
"We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers."7.71Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002)
"Gabapentin has been studied for diverse off-label indications, including alcohol use disorder (AUD)."5.56Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. ( Andrade, C, 2020)
" The primary objective of this study was to compare the efficacy of gabapentin to lorazepam in alleviating sleep disturbances and daytime sleepiness during an episode of alcohol withdrawal."5.12Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. ( Boyle, E; Malcolm, R; Myrick, LH; Randall, PK; Veatch, LM, 2007)
"We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers."3.71Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002)
" Under gabapentin (1800 mg/day) and placebo (0 mg/day) maintenance, participants completed nine separate test sessions (three sessions per week) during which they received an oral solution containing 0, 15, or 30 mg/70 kg OXY in combination with 0, 0."3.11Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. ( Castillo, F; Comer, SD; Evans, SM; Foltin, RW; Jones, JD; Luba, RR; Mogali, S, 2022)
"Gabapentin treatment rapidly titrated to a dosage of 3600 mg/day is associated with a reduction in the proportion of HDD per week and an increase in PDA per week in actively drinking outpatients with AUD."3.01Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder. ( Basaraba, C; Bisaga, A; Brooks, DJ; Carpenter, KM; Levin, FR; Mamczur-Fuller, A; Mariani, JJ; Nunes, EV; Pavlicova, M, 2021)
"More gabapentin-treated individuals had no heavy drinking days (12 of 44 participants [27%]) compared with placebo (4 of 46 participants [9%]), a difference of 18."2.94Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. ( Anton, RF; Book, S; Bristol, E; Hoffman, M; Latham, P; Prisciandaro, J; Voronin, K, 2020)
"Pharmacological treatments for alcohol use disorder show a modest effect, and they are unavailable in certain countries."2.87A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence. ( Chompookham, P; Kalayasiri, R; Nilaban, S; Rukngan, W; Suwanmajo, S; Yoosom, P, 2018)
"Gabapentin is an antiepileptic medication with evidence of benefit in alcohol use disorder patients."2.82Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis. ( Kersten, B; Kunadharaju, R; Mammen, MJ; Mattle, AG; McGrath, P; Sanu, A; Zammit, K, 2022)
"Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics."2.79Gabapentin treatment for alcohol dependence: a randomized clinical trial. ( Begovic, A; Goodell, V; Kyle, M; Mason, BJ; Quello, S; Shadan, F, 2014)
"Gabapentin was associated with significantly greater reductions than placebo on several measures of subjective craving for alcohol as well as for affectively evoked craving."2.74Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. ( Drobes, DJ; Light, JM; Mason, BJ; Williams, LD, 2009)
"Improved treatment of alcohol dependence is a high priority, including defining subtypes that might respond differently."2.74Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. ( Anton, RF; Baros, AM; Latham, PK; Malcolm, R; Myrick, H; Randall, PK; Stewart, SH; Waid, R; Wright, TM, 2009)
"GABAPENTIN REDUCES WITHDRAWAL SYMPTOMS AND IS LESS SEDATING THAN BENZODIAZEPINES (SOR: B, BASED ON 1 MEDIUM-QUALITY RCT)."2.72Which detoxification regimens are effective for alcohol withdrawal syndrome? ( Caspar, R; Fortenberry, K; Leiser, J; Nashelsky, J; Ose, D, 2021)
"Seventeen volunteers without alcohol dependence were tested using a double-blind design with three 3-day long inpatient phases, each separated by at least a 1-week wash-out period."2.72The acute effects of gabapentin in combination with alcohol in heavy drinkers. ( Bisaga, A; Evans, SM, 2006)
"Gabapentin is a calcium channel GABAergic modulator that is widely used for pain."2.58Gabapentin for the treatment of alcohol use disorder. ( Mason, BJ; Quello, S; Shadan, F, 2018)
"Insomnia in patients with alcohol dependence has increasingly become a target of treatment due to its prevalence, persistence, and associations with relapse and suicidal thoughts, as well as randomized controlled studies demonstrating efficacy with behavior therapies and non-addictive medications."2.52Assessment and treatment of insomnia in adult patients with alcohol use disorders. ( Brower, KJ, 2015)
"Studies evaluating gabapentin for alcohol dependence demonstrated dose-dependent benefits for complete abstinence, rates of no heavy drinking, and cravings."2.52The role of gabapentin in the management of alcohol withdrawal and dependence. ( Hall-Flavin, D; Leung, JG; Nelson, S; Schak, KM; Schmidt, KA, 2015)
"Substance use is prevalent in Canada, yet treatment is inaccessible."1.56A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. ( Hulme, J; Sheikh, H; Wiercigroch, D, 2020)
" Recent evidence suggests safety concerns associated with gabapentin including adverse neurologic effects."1.56Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. ( Bryant, KJ; Fiellin, DA; Justice, AC; Morford, KL; Rentsch, CT; Tate, JP, 2020)
"Gabapentin has been studied for diverse off-label indications, including alcohol use disorder (AUD)."1.56Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. ( Andrade, C, 2020)
"Current medications for alcohol use disorder (AUD) have limited efficacy and utilization."1.51Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. ( Bryant, KJ; Fiellin, DA; Justice, AC; Rentsch, CT; Tate, JP, 2019)
"Gabapentin effects were blocked in the presence of a specific GABA(B) receptor antagonist."1.35Cellular and behavioral interactions of gabapentin with alcohol dependence. ( Cruz, MT; Gilpin, NW; Koob, GF; Morse, AC; O'Dell, LE; Roberto, M; Siggins, GR, 2008)

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (5.45)18.2507
2000's16 (29.09)29.6817
2010's16 (29.09)24.3611
2020's20 (36.36)2.80

Authors

AuthorsStudies
Vannier, AGL1
Shay, JES1
Fomin, V1
Patel, SJ1
Schaefer, E1
Goodman, RP1
Luther, J1
Leung, E1
Ngo, DH1
Espinoza, JA1
Beal, LL1
Chang, C1
Baris, DA1
Lackey, BN1
Lane, SD1
Wu, HE1
Bahji, A1
Crockford, D1
El-Guebaly, N1
Castillo, F1
Jones, JD1
Luba, RR1
Mogali, S1
Foltin, RW1
Evans, SM2
Comer, SD1
Mocanu, V1
Wood, E1
Mattle, AG3
McGrath, P3
Sanu, A3
Kunadharaju, R3
Kersten, B3
Zammit, K3
Mammen, MJ3
DeFoster, RE1
Morgan, RJ1
Leung, JG2
Schenzel, H1
Vijapura, P1
Kashiwagi, DT1
Fischer, KM1
Philbrick, KL1
Kung, S1
Ahmed, S1
Stanciu, CN1
Kotapati, PV1
Ahmed, R1
Bhivandkar, S1
Khan, AM1
Afridi, A1
Qureshi, M1
Esang, M1
Andaluz, A1
DeMoss, D1
Claassen, C1
Blair, S1
Hsu, J1
Bakre, S1
Khan, M1
Atem, F1
Rush, AJ1
Wiercigroch, D1
Sheikh, H1
Hulme, J1
Anton, RF6
Latham, P1
Voronin, K3
Book, S2
Hoffman, M2
Prisciandaro, J1
Bristol, E2
Rentsch, CT2
Morford, KL1
Fiellin, DA2
Bryant, KJ2
Justice, AC2
Tate, JP2
Cheng, YC1
Huang, YC1
Huang, WL1
Rose, M1
Andrade, C1
Morley, KC1
Perry, CJ1
Watt, J1
Hurzeler, T1
Leggio, L1
Lawrence, AJ1
Haber, P1
Caspar, R1
Fortenberry, K1
Leiser, J1
Ose, D1
Nashelsky, J1
Weresch, J1
Kirkwood, J1
Korownyk, CS1
Mariani, JJ1
Pavlicova, M1
Basaraba, C1
Mamczur-Fuller, A1
Brooks, DJ1
Bisaga, A2
Carpenter, KM1
Nunes, EV2
Levin, FR1
Bertholet, N1
Prisciandaro, JJ1
Brown, TR1
Mason, BJ3
Quello, S2
Shadan, F2
Pakri Mohamed, RM1
Kumar, J1
Ahmad, SU1
Mohamed, IN1
Chompookham, P1
Rukngan, W1
Nilaban, S1
Suwanmajo, S1
Yoosom, P1
Kalayasiri, R1
Castrén, S1
Mäkelä, N1
Alho, H1
Morrison, M1
Udeh, E1
Burak, M1
Kranzler, HR1
Feinn, R1
Morris, P1
Hartwell, EE1
Goodell, V1
Kyle, M1
Begovic, A1
Brower, KJ4
Hall-Flavin, D1
Nelson, S1
Schmidt, KA1
Schak, KM1
Roberto, M1
Gilpin, NW1
O'Dell, LE1
Cruz, MT1
Morse, AC1
Siggins, GR1
Koob, GF1
Myra Kim, H1
Strobbe, S1
Karam-Hage, MA1
Consens, F1
Zucker, RA1
Clemens, KJ1
Vendruscolo, LF1
Light, JM1
Williams, LD1
Drobes, DJ1
Bonnet, U2
Specka, M2
Hamzavi Abedi, R1
Wiltfang, J1
Scherbaum, N1
Myrick, H7
Baros, AM3
Latham, PK3
Randall, PK5
Wright, TM3
Stewart, SH1
Waid, R1
Malcolm, R3
Waid, LR2
Schacht, JP2
O'Brien, CP1
Li, X1
Henderson, S2
Perugi, G1
Toni, C1
Frare, F1
Ruffolo, G1
Moretti, L1
Torti, C1
Akiskal, HS1
Karam-Hage, M2
Banger, M1
Leweke, FM1
Müller, BW1
Hashemi, T1
Nyhuis, PW1
Kutscher, S1
Burtscheidt, W1
Gastpar, M1
Book, SW1
Anton, R1
Wang, W1
Victorri-Vigneau, C1
Guerlais, M1
Jolliet, P1
Myrick, LH1
Veatch, LM1
Boyle, E1
Furieri, FA1
Nakamura-Palacios, EM1
Bailey, CP1
Molleman, A1
Little, HJ1
Brady, KT1
Chatterjee, CR1
Ringold, AL1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot (Sublocade®) vs Daily Sublingual Buprenorphine With Naloxone (Suboxone®) for the Treatment of O[NCT05594121]Phase 490 participants (Anticipated)Interventional2022-12-31Not yet recruiting
Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects[NCT02349477]Phase 296 participants (Actual)Interventional2014-11-30Completed
Gabapentin for Abstinence Initiation in Alcohol Dependence[NCT01141049]Phase 2/Phase 340 participants (Actual)Interventional2010-08-31Completed
Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial[NCT02771925]Phase 425 participants (Actual)Interventional2016-06-30Terminated (stopped due to Due to poor compliance of patients in the study.)
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903]Phase 477 participants (Actual)Interventional2018-05-15Completed
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776]Phase 254 participants (Actual)Interventional2017-08-07Completed
Gabapentin Treatment of Alcohol Dependence[NCT00391716]Phase 2150 participants (Actual)Interventional2004-02-29Completed
A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome[NCT03012815]Phase 488 participants (Actual)Interventional2017-02-01Completed
A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention[NCT00262639]Phase 2/Phase 360 participants (Actual)Interventional2005-12-31Completed
Gabapentin as an Adjunct to Naltrexone for Alcoholism[NCT00183196]Phase 3150 participants (Actual)Interventional2003-01-31Completed
Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological[NCT03842670]140 participants (Anticipated)Interventional2018-11-14Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With No Drinking Days by AWS Score and Medication

This analysis examines the interaction of medication group with a median split of the baseline Alcohol Withdrawal Scale (AWS) scores on the primary outcome variable (no heavy drinking days, corrected for %dCDT). Participants will report their daily alcohol use with using a daily calendar. AWS ranges from 0 to 44 where higher values correspond with more serious withdrawal (worse outcome). (NCT02349477)
Timeframe: 4 months

InterventionParticipants (Count of Participants)
Low AWS/Gabapentin2
Low AWS/Placebo3
High AWS/Gabapentin10
High AWS/Placebo1

Percent of Subjects With no Drinking Days (PSNDD)

The secondary dependent variable will be percent of subjects with no drinking days (total abstinence). Participants will report their daily alcohol use with using a daily calendar. Abstinence is corrected for %dCDT. (NCT02349477)
Timeframe: 4 months

InterventionParticipants (Count of Participants)
Gabapentin8
Placebo2

Percent of Subjects With no Heavy Drinking Days (PSNHDD)

The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar. No heavy drinking days is corrected for %dCDT. (NCT02349477)
Timeframe: 4 months

InterventionParticipants (Count of Participants)
Gabapentin12
Placebo4

Percent Days of Abstinence From Alcohol

During the course of 8 weeks the medication aims to determine whether it is effective in reducing alcohol consumption, and promoting abstinence in alcohol-dependent patients. (NCT01141049)
Timeframe: assessed for up to 8 weeks, presented at week 8 of trial

Interventionpercent of days abstinent (Mean)
Gabapentin50
Placebo27.5

Percent of Heavy Drinking Days Per Week

percent of heavy drinking days as defined as 5 drinks per day for males and 4 drinks per day for females over the course of a study week. (NCT01141049)
Timeframe: assesed over 8 weeks, presented for week 8 of trial

Interventionpercent of heavy drinking days (Mean)
Gabapentin22.5
Placebo53.9

"VAS Score 1: How Much Pain do You Feel in Your Operative Site When Resting?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)

Interventionscore on 10-point scale (Mean)
Standard of Care2.26
Postoperative Gabapentin Regimen2.46

"VAS Score 2: How Much Pain do You Feel in Your Operative Site When Moving?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care3.84
Postoperative Gabapentin Regimen3.54

"VAS Score 3: How Well Are You Sleeping?"

Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care5.73
Postoperative Gabapentin Regimen6.38

"VAS Score 4: How Bad is Your Nausea?"

Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care0.36
Postoperative Gabapentin Regimen0.17

"VAS Score 5: How Satisfied Are You With Your Pain Management?"

Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care7.83
Postoperative Gabapentin Regimen8.48

Days Taking Opioids

Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventiondays (Mean)
Standard of Care14.8
Postoperative Gabapentin Regimen18.7

Opioid Consumption

Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).

Interventionmorphine equivalents (Mean)
Standard of Care287.0
Postoperative Gabapentin Regimen281.1

Prefrontal GABA+ Concentrations

Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine3.90
Gabapentin3.93
Placebo Oral Tablet3.73

Prefrontal Glx Concentrations

Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine21.59
Gabapentin21.69
Placebo Oral Tablet22.25

Craving

Alcohol Craving Questionnaire has 12 questions about alcohol craving which are each scored 1-7, then summed for a weekly score between 7 and 84, with higher scores indicating greater craving. Cumulative mean total craving scores are tested by ANOVA for differences between treatment groups. (NCT00391716)
Timeframe: 12-week

Interventionunits on a scale (Mean)
Gabapentin 900mg Daily33.66
Gabapentin 1800mg Daily32.31
Placebo Daily34.27

Drinking

Rate of complete abstinence was defined as the number of participants who drank no alcohol during 12 weeks of treatment, where the denominator is the intent to treat population. Rate of heavy drinking abstinence is defined as no heavy drinking days while on study (4 or more for women, 5 or more for men). (NCT00391716)
Timeframe: 12-week

Interventionparticipants (Number)
Gabapentin 900mg Daily6
Gabapentin 1800mg Daily8
Placebo Daily2

Mood

Beck Depression Inventory II consists of 21 questions assessing depression symptoms answered with scores between 0 and 3, summed for a weekly total score between 0 and 63; higher scores indicate more depression. The cumulative mean total depression scores over the 12 week study are tested by ANOVA for differences in cumulative means between treatment groups. (NCT00391716)
Timeframe: 12-week

Interventionunits on a scale (Mean)
Gabapentin 900mg Daily5.08
Gabapentin 1800mg Daily3.62
Placebo Daily5.40

Sleep

The Pittsburgh Sleep Questionnaire Inventory consists of 9 questions about sleep habits which are answered on a scale of 0-3. Results are sorted into 7 sub scales re-scored 0-3, then sub scales are summed for a weekly total score between 0 and 21, with higher total scores indicating greater sleep impairment. Cumulative mean total sleep scores over the 12 weeks of study are assessed by ANOVA for differences between treatment groups. (NCT00391716)
Timeframe: 12-week

Interventionunits on a scale (Mean)
Gabapentin 900mg Daily4.04
Gabapentin 1800mg Daily3.24
Placebo Daily4.50

Change in Anxiety Symptoms as Measured by the Generalized Anxiety Disorder-7 (GAD-7) Scale

GAD-7 is GAD-7 is a 7-item self-administered scale of Generalized Anxiety Disorder symptoms (0 = not at all to 3 = nearly every day). Total scores range from 0 to 21. Total scores of 0-4 = minimal anxiety, Total scores of 5-9 = mild anxiety, total scores of 10-14 = moderate anxiety and total scores of 15-21 = severe anxiety. (NCT03012815)
Timeframe: Baseline and 2 days

Interventionscore on a scale (Mean)
Gabapentin-0.07
Benzodiazepine-3.79

Change in Cravings as Assessed by the Penn Alcohol Craving (PACS) Scale

PACS is a 5 item self-rated scale of alcohol craving (0 = none to 6 = strong urge). Total scores range from 0 (little craving for alcohol) to 30 (irresistible urge to drink alcohol) (NCT03012815)
Timeframe: Baseline and 2 days

Interventionscore on a scale (Mean)
Gabapentin-8.12
Benzodiazepine-8.45

Change in Sleepiness as Assessed by the Epworth Sleepiness Scale

The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their daytime sleepiness. (NCT03012815)
Timeframe: Baseline and 2 days

Interventionscore on a scale (Mean)
Gabapentin-0.03
Benzodiazepine0.07

Maximun Alcohol Withdrawal Severity Per CIWA-Ar Scale

CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: 4 days

Interventionscore on a scale (Mean)
Gabapentin13.15
Benzodiazepine12.81

Mean Length of Hospital Stay

The length of hospital stay for Alcohol withdrawal syndrome. The time interval between admission and either discharge or the time at which Clinical Institute Withdrawal Assessment - Alcohol revised (CIWA-Ar) scores are <10 for 36 hours (up to 240 hours). Measured in hours. CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.

Interventionhours (Mean)
Gabapentin44.91
Benzodiazepine50.50

Mean Total Benzodiazepine Use

The total amount of benzodiazepines administered. Measured by lorazepam equivalent, mg. (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.

Interventionmilligrams (Mean)
Gabapentin5.2
Benzodiazepine10.8

Number of Participants Experiencing Seizure

The number of subjects who developed seizure during their hospitalization. (NCT03012815)
Timeframe: During hospitalization (up to 240 hours).

InterventionParticipants (Count of Participants)
Gabapentin0
Benzodiazepine0

Number of Participants With Delirium Tremens (DT)

The number of participants experiencing delirium tremens during their hospitalization (between admission and discharge). (NCT03012815)
Timeframe: During hospitalization (up to 240 hours)

InterventionParticipants (Count of Participants)
Gabapentin0
Benzodiazepine0

Percent Days Abstinent

percent days abstinent during treatment (NCT00262639)
Timeframe: Weeks 1 to 6

Interventionpercent days (Mean)
Low CIWA Flumazenil/Gabapentin70.8
Low CIWAar Placebo86.1
High CIWAar Placebo75.9
High CIWAar Flumazenil/Gabapentin95.9

Percent Subjects Completely Abstinent

percent of subjects completely abstinent during the six week medication study study (NCT00262639)
Timeframe: 6 week trial

Interventionpercent of participants (Number)
Low CIWA Flumazenil/Gabapentin44
Low CIWAar Placebo19
High CIWAar Placebo33
High CIWAar Flumazenil/Gabapentin71

Time to Relapse to Drinking

Time to relapse drinking which is 5 standard drinks perday for males and 4 standard drinks per day for females. Subjects had a minimum of 4 days of abstinence prior to being entered into the protocol. (NCT00183196)
Timeframe: 16 weeks

Interventiondays (Mean)
Naltrexone Plus Gabapentin and CBI69.9
Naltrexone Plus Placebo and CBI59.6
Placebo Plus Placebo Plus CBI57.3

Reviews

15 reviews available for gabapentin and Alcoholism

ArticleYear
Management of Post-Acute Alcohol Withdrawal: A Mixed-Studies Scoping Review.
    Journal of studies on alcohol and drugs, 2022, Volume: 83, Issue:4

    Topics: Alcoholism; Anticonvulsants; Benzodiazepines; Gabapentin; Humans; Substance Withdrawal Syndrome

2022
Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review.
    Addiction science & clinical practice, 2022, 11-08, Volume: 17, Issue:1

    Topics: Alcoholism; Anxiety; Anxiety Disorders; Comorbidity; Gabapentin; Humans; Male; Middle Aged; Randomiz

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review.
    The primary care companion for CNS disorders, 2019, Aug-22, Volume: 21, Issue:4

    Topics: Alcoholism; Craving; Excitatory Amino Acid Antagonists; Gabapentin; Humans; Substance Withdrawal Syn

2019
Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis.
    Human psychopharmacology, 2020, Volume: 35, Issue:6

    Topics: Alcohol Drinking; Alcoholism; Craving; Gabapentin; Humans; Pregabalin; Randomized Controlled Trials

2020
New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies.
    Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:10

    Topics: Alcoholism; Europe; Gabapentin; Humans; Topiramate

2021
Which detoxification regimens are effective for alcohol withdrawal syndrome?
    The Journal of family practice, 2021, Volume: 70, Issue:2

    Topics: Alcoholism; Anticonvulsants; Benzodiazepines; Carbamazepine; Gabapentin; Humans; Substance Withdrawa

2021
Gabapentin for the treatment of alcohol use disorder.
    Expert opinion on investigational drugs, 2018, Volume: 27, Issue:1

    Topics: Alcohol Drinking; Alcoholism; Amines; Animals; Calcium Channel Blockers; Cyclohexanecarboxylic Acids

2018
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
    Current drug targets, 2018, Volume: 19, Issue:12

    Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans;

2018
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
    Current opinion in psychiatry, 2019, Volume: 32, Issue:4

    Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapent

2019
A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder.
    Addiction (Abingdon, England), 2019, Volume: 114, Issue:9

    Topics: Alcohol Abstinence; Alcoholism; Excitatory Amino Acid Antagonists; Gabapentin; Humans; Randomized Co

2019
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
    Alcohol (Fayetteville, N.Y.), 2015, Volume: 49, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amines; Anti-Anxiety Agents; Anticonvulsants; Antipsych

2015
The role of gabapentin in the management of alcohol withdrawal and dependence.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:8

    Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin

2015
The role of gabapentin in the management of alcohol withdrawal and dependence.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:8

    Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin

2015
The role of gabapentin in the management of alcohol withdrawal and dependence.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:8

    Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin

2015
The role of gabapentin in the management of alcohol withdrawal and dependence.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:8

    Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin

2015
Anxious to drink: gabapentin normalizes GABAergic transmission in the central amygdala and reduces symptoms of ethanol dependence.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Sep-10, Volume: 28, Issue:37

    Topics: Alcoholism; Amines; Amygdala; Animals; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Gabapentin;

2008
Novel anticonvulsants in the treatment of alcoholism.
    Expert opinion on investigational drugs, 2005, Volume: 14, Issue:4

    Topics: Alcohol Deterrents; Alcoholism; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids;

2005

Trials

21 trials available for gabapentin and Alcoholism

ArticleYear
Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder.
    Pharmacology, biochemistry, and behavior, 2022, Volume: 221

    Topics: Alcoholism; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Ethanol; Gabapentin; Humans

2022
Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial.
    Substance use & misuse, 2023, Volume: 58, Issue:13

    Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Benzodiazepines; Gabapentin; Hospitals; Humans; Retr

2023
Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.
    JAMA internal medicine, 2020, 05-01, Volume: 180, Issue:5

    Topics: Adult; Alcohol Abstinence; Alcoholism; Double-Blind Method; Excitatory Amino Acid Antagonists; Femal

2020
Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder.
    Alcoholism, clinical and experimental research, 2021, Volume: 45, Issue:8

    Topics: Adult; Alcoholism; Anticonvulsants; Female; Gabapentin; Humans; Male; Medication Adherence; Middle A

2021
Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial.
    The American journal of psychiatry, 2021, 09-01, Volume: 178, Issue:9

    Topics: Adult; Alcoholism; Double-Blind Method; Female; Gabapentin; gamma-Aminobutyric Acid; Glutamic Acid;

2021
A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence.
    Psychiatry research, 2018, Volume: 270

    Topics: Adolescent; Adult; Aged; Alcoholism; Excitatory Amino Acid Antagonists; Female; Gabapentin; Hospital

2018
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox

2014
A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.
    Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:8

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Dose-Res

2008
Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.
    Addiction biology, 2009, Volume: 14, Issue:1

    Topics: Adult; Affect; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Amines; Arousal; Cues; C

2009
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4

    Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub

2009
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4

    Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub

2009
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4

    Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub

2009
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4

    Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub

2009
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
    The American journal of psychiatry, 2011, Volume: 168, Issue:7

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu

2011
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
    The American journal of psychiatry, 2011, Volume: 168, Issue:7

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu

2011
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
    The American journal of psychiatry, 2011, Volume: 168, Issue:7

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu

2011
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
    The American journal of psychiatry, 2011, Volume: 168, Issue:7

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu

2011
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:11

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C

2011
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:11

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C

2011
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:11

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C

2011
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:11

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C

2011
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.
    Psychopharmacology, 2013, Volume: 227, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Brain; Cues; Cyclohexanecarboxylic Acids; Drug Therapy,

2013
Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.
    Psychiatry and clinical neurosciences, 2003, Volume: 57, Issue:5

    Topics: Acetates; Alcoholism; Amines; Antidepressive Agents, Second-Generation; Cyclohexanecarboxylic Acids;

2003
Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:5

    Topics: Acetates; Adult; Alcoholism; Amines; Analysis of Variance; Chi-Square Distribution; Cyclohexanecarbo

2003
The acute effects of gabapentin in combination with alcohol in heavy drinkers.
    Drug and alcohol dependence, 2006, Jun-09, Volume: 83, Issue:1

    Topics: Adult; Alcoholic Intoxication; Alcoholism; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dos

2006
A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm.
    Alcoholism, clinical and experimental research, 2007, Volume: 31, Issue:2

    Topics: Adult; Aged; Alcohol-Related Disorders; Alcoholism; Amines; Anticonvulsants; Cyclohexanecarboxylic A

2007
Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2007, Feb-15, Volume: 3, Issue:1

    Topics: Adult; Aged; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disorders of Excessive Somnolence; Dou

2007
Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11

    Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Ambulatory Care; Amines; Blood-Brain Barrie

2007
Gabapentin treatment of alcohol withdrawal.
    The American journal of psychiatry, 1998, Volume: 155, Issue:11

    Topics: Acetates; Adult; Alcohol Withdrawal Delirium; Alcoholism; Ambulatory Care; Amines; Anticonvulsants;

1998
Gabapentin treatment for insomnia associated with alcohol dependence.
    The American journal of psychiatry, 2000, Volume: 157, Issue:1

    Topics: Acetates; Adult; Alcoholism; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Fema

2000

Other Studies

19 other studies available for gabapentin and Alcoholism

ArticleYear
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
    JAMA network open, 2022, 05-02, Volume: 5, Issue:5

    Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Nal

2022
A Retrospective Study of the Adjunctive Use of Gabapentin With Benzodiazepines for the Treatment of Benzodiazepine Withdrawal.
    Journal of psychiatric practice, 2022, 07-01, Volume: 28, Issue:4

    Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom

2022
Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study.
    The American journal of drug and alcohol abuse, 2020, Volume: 46, Issue:1

    Topics: Adult; Alcoholism; Benzodiazepines; Drug Tapering; Female; Gabapentin; Humans; Lorazepam; Male; Midd

2020
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
    Substance abuse treatment, prevention, and policy, 2020, 01-13, Volume: 15, Issue:1

    Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergen

2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder.
    Alcoholism, clinical and experimental research, 2020, Volume: 44, Issue:9

    Topics: Accidental Falls; Alcoholism; Cohort Studies; Comorbidity; Confusion; Drug Interactions; Excitatory

2020
Gabapentin reduced drinking in patients with alcohol use disorder and alcohol withdrawal symptoms.
    Annals of internal medicine, 2020, 07-21, Volume: 173, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Withdrawal Synd

2020
Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach.
    The Journal of clinical psychiatry, 2020, 11-24, Volume: 81, Issue:6

    Topics: Adult; Alcohol Abstinence; Alcohol-Related Disorders; Alcoholism; Excitatory Amino Acid Antagonists;

2020
Gabapentin for alcohol use disorder.
    Canadian family physician Medecin de famille canadien, 2021, Volume: 67, Issue:4

    Topics: Alcoholism; Gabapentin; Humans; Substance Withdrawal Syndrome; Treatment Outcome

2021
    Revue medicale suisse, 2021, 06-23, Volume: 17, Issue:744

    Topics: Alcoholism; Gabapentin; Humans; Substance Withdrawal Syndrome

2021
Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder.
    Alcoholism, clinical and experimental research, 2019, Volume: 43, Issue:3

    Topics: Adult; Alcohol Drinking; Alcoholism; Case-Control Studies; Comorbidity; Dose-Response Relationship,

2019
Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal.
    The American journal of drug and alcohol abuse, 2019, Volume: 45, Issue:4

    Topics: Acute Disease; Adult; Alcoholism; Electronic Health Records; Endpoint Determination; Female; GABA Ag

2019
Gabapentin: a new addition to the armamentarium for alcohol dependence?
    JAMA internal medicine, 2014, Volume: 174, Issue:1

    Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Female; GABA Modulators; Gabapentin; gamma-Aminobut

2014
Cellular and behavioral interactions of gabapentin with alcohol dependence.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, May-28, Volume: 28, Issue:22

    Topics: Alcoholism; Amines; Amygdala; Animals; Behavior, Animal; Central Nervous System Depressants; Cyclohe

2008
Severe protracted alcohol withdrawal syndrome: prevalence and pharmacological treatment at an inpatient detoxification unit--a naturalistic study.
    Pharmacopsychiatry, 2009, Volume: 42, Issue:2

    Topics: Adult; Aged; Alcoholism; Amines; Anticonvulsants; Chlormethiazole; Clonazepam; Cyclohexanecarboxylic

2009
Adapting treatment to patient problems.
    The American journal of psychiatry, 2011, Volume: 168, Issue:7

    Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combina

2011
Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:6

    Topics: Acetates; Adult; Aged; Alcoholism; Amines; Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bip

2002
Abuse, dependency and withdrawal with gabapentin: a first case report.
    Pharmacopsychiatry, 2007, Volume: 40, Issue:1

    Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A

2007
Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption.
    British journal of pharmacology, 1998, Volume: 123, Issue:2

    Topics: Acetates; Alcoholism; Amines; Animals; Behavior, Animal; Calcium Channel Blockers; Cyclohexanecarbox

1998
A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:9

    Topics: Acetates; Adult; Alcohol Drinking; Alcoholism; Amines; Animals; Anticonvulsants; Comorbidity; Cycloh

1999